Sanofi India financials

·Pharma & HealthChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹492cr+3.4% on Q2 FY26
Net profit
₹117cr+53.6% on Q2 FY26
EBITDA margin
32.8%+4.6 pts on Q2 FY26
EPS
₹50.67+53.6% on Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue492475+3.4%
EBITDA161134+20.1%
EBITDA margin32.8%28.2%+4.6 pts
Profit before tax158102+54.2%
Net profit11776.0+53.6%
EPS₹50.67₹32.99+53.6%

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹492 crNet profit₹117 crNet margin23.7%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Dec 2025FY25Dec 2024FY24Dec 2023FY23Dec 2022FY22 and earlierAlpha Plus
6,882————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2632632843931,005
6,619————
1,8221,8372,0132,8512,770
—−8.7%−29.4%+2.9%—
510491491804704
28.0%26.7%24.4%28.2%25.4%
473454454764663
365327414603621
20.0%17.8%20.5%21.2%22.4%
₹158.48₹142.04₹179.78₹262.26₹269.83
—−21.0%−31.4%−2.8%—
—438462231399
—−25.7−36.4−34.3−22.2
413413425197377
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SANOFI₹2,992.00

Sanofi India Limited

· Pharma & Health
₹ CrorePeersSENORESINNOVACAPPGHLMOREPENLABIOLCPSANOFICONRFDCORCHPHARMAMcap ₹6,882 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/12/2022
FY24
31/12/2023
FY25
31/12/2024
FY26
31/12/2025
Current/LTM
TTM · last close
Market Capitalization————6,881.6
- Cash, Equiv & ST Investments1,004.9392.9283.8262.9262.9
Enterprise Value————6,618.7
Revenue2,770.12,851.12,013.21,837.41,821.5
Growth %, YoY—+2.9-29.4-8.7—
EBITDA704.4804.0490.8491.3509.6
Margin %25.4328.2024.3826.7427.98
EBIT662.5764.4454.1454.0473.4
Net Income620.6603.2413.5326.7364.5
Margin %22.4021.1620.5417.7820.01
EPS, Adj (current shares)269.83262.26179.78142.04158.48
Growth %, YoY—-2.8-31.4-21.0—
Cash from Operations398.7230.8461.7438.3—
Capital Expenditures-22.2-34.3-36.4-25.7—
Free Cash Flow376.5196.5425.3412.6412.6
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Sanofi India financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Sanofi India (NSE: SANOFI) had a market capitalisation of ₹7,336 crore at the 29 October 2026 close (₹3,189.50 a share), a PE ratio of 20.1 on the last four quarters' profit and a price-to-book ratio of 8.88. In the year to December 2025 its standalone net profit was ₹327 crore on revenue of ₹1,837 crore; in Q2 FY27 (July–September 2026) it was ₹117 crore, up 53.6% year on year. It had no borrowings on 30 June 2026. Promoters held 60.40% of the shares on 30 September 2026.

Sanofi India Q2 FY27 results
filed 29 October 2026
Share price used
₹3,189.50 · 29 October 2026 close
Latest balance sheet
30 June 2026
Shareholding pattern
30 September 2026

Sanofi India at a glance · standalone

Market cap
₹7,336 Crat ₹3,189.50 · 29 Oct close
PE ratio (last 4 quarters)
20.122.5 on the year to December 2025 profit
Price to book (PB)
8.88book value ₹359.13 a share
ROE (the year to December 2025)
40.6%−3.5 pts vs the year to December 2024ROCE 54.8%
Debt to equity
0.00net cash ₹369 Cr
Promoter holding
60.40%unchanged vs 30 Jun 202630 September 2026
Dividend yield
3.86%₹123 a share in 12 months
Net worth
₹826 Cr+5.6% vs 30 Jun 202530 June 2026
Free cash flow (the year to December 2025)
₹413 Cr−3.0% vs the year to December 2024

Questions

What is the Sanofi India PE ratio today?

Sanofi India's PE ratio is 20.1 at the 29 October 2026 close (₹3,189.50 a share): a market capitalisation of ₹7,336 crore divided by standalone net profit of ₹365 crore over the last four quarters (Q3 FY26 to Q2 FY27). On the year to December 2025 net profit (₹327 crore) it is 22.5.

What is the Sanofi India PB ratio (price to book value)?

Sanofi India's price-to-book (PB) ratio is 8.88 at the 29 October 2026 close: a market capitalisation of ₹7,336 crore divided by shareholders' equity (book value) of ₹826 crore on 30 June 2026. That is a book value of ₹359.13 per share against a share price of ₹3,189.50.

What is the Sanofi India net worth?

Sanofi India's net worth — shareholders' equity in its standalone balance sheet — was ₹826 crore on 30 June 2026, up 5.6% from ₹782 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹7,336 crore at the 29 October 2026 close.

What is the Sanofi India market cap?

Sanofi India's market capitalisation was ₹7,336 crore at the 29 October 2026 close: 2.3 crore shares at ₹3,189.50 each.

Is Sanofi India debt free?

Yes. Sanofi India had no borrowings on 30 June 2026 (standalone balance sheet), and it held ₹369 crore of cash, bank balances and current investments.

What is the Sanofi India debt to equity ratio?

Sanofi India's debt-to-equity ratio was 0.00 on 30 June 2026: no borrowings against total equity of ₹826 crore. A year earlier, on 30 June 2025, it was 0.00.

What is the Sanofi India ROE and ROCE?

In the year to December 2025, Sanofi India's return on equity (ROE) was 40.6% and its return on capital employed (ROCE) was 54.8%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In the year to December 2024, ROE was 44.1% and ROCE 46.4%.

What is the Sanofi India shareholding pattern?

On 30 September 2026, Sanofi India's shares were held by promoters 60.40%, foreign portfolio investors (FII/FPI) 5.73%, domestic institutions (DII) 19.41% (including mutual funds at 8.62%) and retail and other non-institutional investors 14.46%. Over the year, FII holding was up 0.16 percentage points from 5.57% and DII holding was down 2.88 percentage points from 22.29%.

What are the Sanofi India latest quarterly results?

Sanofi India's latest results are for Q2 FY27 (July–September 2026), filed on 29 October 2026: standalone net profit ₹117 crore, up 53.6% from ₹76 crore in Q2 FY26; revenue from operations ₹492 crore, up 3.4% year on year.

What is the Sanofi India book value per share?

Sanofi India's book value per share was ₹359.13 on 30 June 2026: shareholders' equity of ₹826 crore divided by the 2.3 crore shares in issue, up 5.6% from ₹340.04 a year earlier. The share price at the 29 October 2026 close was ₹3,189.50.

What is the Sanofi India dividend yield?

Sanofi India's dividend yield is 3.86% at the 29 October 2026 close: dividends of ₹123 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹3,189.50. They were ₹48 on 22 April 2026 and ₹75 on 7 November 2025 (interim).

What is the Sanofi India free cash flow?

In the year to December 2025, Sanofi India generated ₹438 crore of cash from operations and spent ₹25.7 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹413 crore. In the year to December 2024 it was ₹425 crore.

What is the Sanofi India EPS?

Sanofi India's basic earnings per share (EPS) were ₹141.85 in the year to December 2025, against ₹179.00 in the year to December 2024. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹158.27.

What is the Sanofi India dividend in 2026 and its record date?

In 2026, Sanofi India has declared one dividend: ₹48 with record date 22 April 2026.

What is the Sanofi India promoter holding?

Promoters held 60.40% of Sanofi India on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

What is the Sanofi India revenue and profit in the year to December 2025?

In the year to December 2025 (January 2024–December 2025), Sanofi India's standalone net profit was ₹327 crore, down 21.0% from ₹414 crore in the year to December 2024, on revenue from operations of ₹1,837 crore (down 8.7%). Over three years, from the year to December 2022, net profit was down 47.4%.

When are the Sanofi India next results?

Sanofi India has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

Where do these Sanofi India figures come from?

From Sanofi India's own standalone results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Standalone figures from the company's filings with NSE; prices are NSE closing prices.